Serial quantitative coronary angiography and coronary events

被引:32
作者
Mack, WJ
Xiang, M
Selzer, RH
Hodis, HN
机构
[1] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[2] Univ So Calif, Dept Med, Atherosclerosis Res Unit, Div Cardiol, Los Angeles, CA 90089 USA
[3] CALTECH, Jet Prop Lab, Pasadena, CA USA
关键词
D O I
10.1067/mhj.2000.105702
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Although assessment of progression of atherosclerosis by quantitative coronary angiography (QCA) is used as a surrogate for coronary events, no validation study has compared the several QCA measures used. Methods and Results The Cholesterol Lowering Atherosclerosis Study was a clinico trial testing the efficacy of colestipol-niacin on the progression of coronary atherosclerosis. Baseline/2-year coronary angiograms were obtained on 156 men with prior coronary artery bypass graft surgery. Changes in percent diameter stenosis and minimum lumen diameter (both measured in coronary lesions and segments) and coronary segment measures of average diameter, percent involvement, and vessel edge roughness were measured by QCA. Coronary events ascertained over 12 years of follow-up included myocardial infarction (MI), coronary death, and coronary artery revascularizations. Proportional hazards models evaluated the relation between QCA change measures and coronary events. Changes in percent diameter stenosis and minimum lumen diameter of coronary artery lesions were significantly related to the risk of MJ/coronary death. All QCA measures were significantly related to the risk of any coronary event. Relative risks for each QCA measure were of similar magnitude when estimated separately within each treatment group. Change in minimum lumen diameter of lesions was the only measure independently associated with the risk of coronary events. Conclusions ail oca measures of progression of coronary artery disease were related to all coronary events (including revascularizations). Only QCA measures of lesion progression were related to MI/coronary death. QCA measures of lesion change may be better surrogate end points for "hard" coronary events than measures of change in coronary segments.
引用
收藏
页码:993 / 999
页数:7
相关论文
共 9 条
[1]   Progression of coronary artery disease predicts clinical coronary events - Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study [J].
Azen, SP ;
Mack, WJ ;
CashinHemphill, L ;
LaBree, L ;
Shircore, AM ;
Selzer, RH ;
Blankenhorn, DH ;
Hodis, HN .
CIRCULATION, 1996, 93 (01) :34-41
[2]   EVALUATION OF COLESTIPOL NIACIN THERAPY WITH COMPUTER-DERIVED CORONARY END-POINT MEASURES - A COMPARISON OF DIFFERENT MEASURES OF TREATMENT EFFECT [J].
BLANKENHORN, DH ;
SELZER, RH ;
MACK, WJ ;
CRAWFORD, DW ;
POGODA, J ;
LEE, PL ;
SHIRCORE, AM ;
AZEN, SP .
CIRCULATION, 1992, 86 (06) :1701-1709
[3]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[4]   CHANGES IN SEQUENTIAL CORONARY ARTERIOGRAMS AND SUBSEQUENT CORONARY EVENTS [J].
BUCHWALD, H ;
MATTS, JP ;
FITCH, LL ;
CAMPOS, CT ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
PEARCE, MB ;
BISSETT, JK ;
EDMISTON, WA ;
SAWIN, HS ;
WEBER, FJ ;
VARCO, RL ;
CAMPBELL, GS ;
YELLIN, AE ;
SMINK, RD ;
LONG, JM ;
HANSEN, BJ ;
CHALMERS, TC ;
MEIER, P ;
STAMLER, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (11) :1429-1433
[5]   EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
VARCO, RL ;
MATTS, JP ;
LONG, JM ;
FITCH, LL ;
CAMPBELL, GS ;
PEARCE, MB ;
YELLIN, AE ;
EDMISTON, WA ;
SMINK, RD ;
SAWIN, HS ;
CAMPOS, CT ;
HANSEN, BJ ;
TUNA, N ;
KARNEGIS, JN ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
BISSETT, JK ;
WEBER, FJ ;
STEVENSON, JW ;
LEON, AS ;
CHALMERS, TC .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955
[6]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[7]   Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis [J].
Mack, WJ ;
Hodis, HN .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1996, 30 :S37-S53
[8]   A CONTROLLED CLINICAL-TRIAL TO ASSESS THE EFFECT OF A CALCIUM-CHANNEL BLOCKER ON THE PROGRESSION OF CORONARY ATHEROSCLEROSIS [J].
WATERS, D ;
LESPERANCE, J ;
FRANCETICH, M ;
CAUSEY, D ;
THEROUX, P ;
CHIANG, YK ;
HUDON, G ;
LEMARBRE, L ;
REITMAN, M ;
JOYAL, M ;
GOSSELIN, G ;
DYRDA, I ;
MACER, J ;
HAVEL, RJ .
CIRCULATION, 1990, 82 (06) :1940-1953
[9]   PROGNOSTIC-SIGNIFICANCE OF PROGRESSION OF CORONARY ATHEROSCLEROSIS [J].
WATERS, D ;
CRAVEN, TE ;
LESPERANCE, J .
CIRCULATION, 1993, 87 (04) :1067-1075